TY - JOUR
T1 - The multiple-dose pharmacokinetics of fluvoxamine in children and adolescentS
AU - ZumBrunnen, T.
AU - Lu, Z.
AU - Chang, J.
AU - Nezamus, J.
AU - Eller, M.
AU - Labellarte, M.
AU - Brennan, J.
N1 - Copyright:
Copyright 2006 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Fluvoxamine (FL) is an SSRI used in the treatment of pediatric OCD. To determine the pharmacokinetics (PK) of FL in children (CH), aged 6-11, and adolescents (AD) aged 12-17 and to compare the PK in AD to the PK of adults, 43 CH and AD patients were enrolled and titrated to a FL dose of 100 and 150 mg twice daily, respectively. PK sampling was conducted after administration of FL doses between 25 mg to 150 mg. PK parameters were calculated and adjusted for body weight. Mean steady-state clearance (CLss) values are given below. Mean CLss (L/h/kg) Dose(mg) 25 50 100 150 Child 0.97 0.43 0.39 NA Adolescent 1.5 1.1 0.61 0.71 Adult NA NA NA 0.46 CLss in CH was 40% to 65% of that observed in AD. CLss was 54% higher in AD compared to adults. FL was well tolerated by the CH and AD population. Based on PK, these results suggest that FL doses up to 300 mg/day, as indicated in adults, may be useful in the treatment of OCD in AD.
AB - Fluvoxamine (FL) is an SSRI used in the treatment of pediatric OCD. To determine the pharmacokinetics (PK) of FL in children (CH), aged 6-11, and adolescents (AD) aged 12-17 and to compare the PK in AD to the PK of adults, 43 CH and AD patients were enrolled and titrated to a FL dose of 100 and 150 mg twice daily, respectively. PK sampling was conducted after administration of FL doses between 25 mg to 150 mg. PK parameters were calculated and adjusted for body weight. Mean steady-state clearance (CLss) values are given below. Mean CLss (L/h/kg) Dose(mg) 25 50 100 150 Child 0.97 0.43 0.39 NA Adolescent 1.5 1.1 0.61 0.71 Adult NA NA NA 0.46 CLss in CH was 40% to 65% of that observed in AD. CLss was 54% higher in AD compared to adults. FL was well tolerated by the CH and AD population. Based on PK, these results suggest that FL doses up to 300 mg/day, as indicated in adults, may be useful in the treatment of OCD in AD.
UR - http://www.scopus.com/inward/record.url?scp=0001791798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0001791798&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0001791798
SN - 0009-9236
VL - 69
SP - P82
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 2
ER -